Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Gynae 2021 | Overcoming resistance to PARPi in ovarian cancer

Overcoming resistance to PARP inhibitions is an area of unmet need in ovarian cancer. Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy, speaks on the importance of elucidating the mechanisms of PARP inhibiton resistance in ovarian cancer, and its importance in terms of improving patient stratification for therapeutic strategies. This interview took place at the ESMO Gynaecological Cancers Virtual Congress 2021.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.